Intellia Therapeutics, Inc. (LON:0JBU)

Market Cap	630.50M
Revenue (ttm)	46.23M
Net Income (ttm)	-414.58M
Shares Out	n/a
EPS (ttm)	-4.19
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	9,175
Average Volume	16,278
Open	6.86
Previous Close	6.94
Day's Range	6.84 - 7.16
52-Week Range	6.97 - 46.91
Beta	n/a
RSI	53.94
Earnings Date	May 8, 2025

About Intellia Therapeutics

Intellia Therapeutics, Inc., a clinical-stage gene editing company, focuses on the development of curative genome editing treatments. The company’s in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 that is in Phase 1/2 study for the treatment of hereditary angioedema. It also focusses on the research of proprietary programs focused on developing engineered cell therapies to treat various cancers and autoimmune diseases. The company has license and collaboration a...

• Industry: Medical - Pharmaceuticals
• Sector: Healthcare
• Founded: 2014
• Employees: 403
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0JBU

Financial Performance

In 2024, Intellia Therapeutics's revenue was $57.88 million, an increase of 59.55% compared to the previous year's $36.28 million. Losses were -$519.02 million, 7.86% more than in 2023.

Financial numbers in USD